Skip to main content
. Author manuscript; available in PMC: 2024 Apr 30.
Published in final edited form as: Sci Transl Med. 2020 Nov 18;12(570):eaaz5327. doi: 10.1126/scitranslmed.aaz5327

Fig. 4. Presence of the inhibitory receptor CD32 on ACPA+ MBCs and TT-specific MBCs from patients with established RA.

Fig. 4

(A) Abundance of CD32 on the surface of ACPA+ or TT-specific MBCs (n = 7). (B) Abundance of intracellular CD32 in ACPA+ or ACPA− MBCs (n = 4). Connected dots depict data from individual patient samples. *P ≤ 0.05, **P ≤ 0.01. One-way ANOVA with Dunn’s multiple comparisons test in (A), two-tailed Wilcoxon signed-rank test in (B). n = number of donors.